DB:2CB

Stock Analysis Report

Executive Summary

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Calithera Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2CB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-20.0%

2CB

-11.1%

DE Biotechs

-9.1%

DE Market


1 Year Return

15.9%

2CB

-2.9%

DE Biotechs

2.9%

DE Market

Return vs Industry: 2CB exceeded the German Biotechs industry which returned -2.9% over the past year.

Return vs Market: 2CB exceeded the German Market which returned 2.9% over the past year.


Shareholder returns

2CBIndustryMarket
7 Day-20.0%-11.1%-9.1%
30 Day-7.4%-12.8%-7.2%
90 Day35.9%-9.6%-6.5%
1 Year15.9%15.9%-2.7%-2.9%6.1%2.9%
3 Year-50.2%-50.2%25.8%24.4%3.5%-5.6%
5 Year-61.0%-61.0%1.6%-0.5%8.0%-6.8%

Price Volatility Vs. Market

How volatile is Calithera Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Calithera Biosciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2CB (€6.2) is trading below our estimate of fair value (€21.22)

Significantly Below Fair Value: 2CB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2CB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2CB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2CB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2CB is good value based on its PB Ratio (3x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Calithera Biosciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

38.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2CB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2CB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2CB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2CB's revenue (55.7% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: 2CB's revenue (55.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2CB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Calithera Biosciences performed over the past 5 years?

-23.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2CB is currently unprofitable.

Growing Profit Margin: 2CB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2CB is unprofitable, and losses have increased over the past 5 years at a rate of -23.8% per year.

Accelerating Growth: Unable to compare 2CB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2CB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 2CB has a negative Return on Equity (-72.63%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Calithera Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: 2CB's short term assets ($136.8M) exceed its short term liabilities ($18.5M).

Long Term Liabilities: 2CB's short term assets ($136.8M) exceed its long term liabilities ($7.2M).


Debt to Equity History and Analysis

Debt Level: 2CB is debt free.

Reducing Debt: 2CB has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 2CB has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 2CB's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2CB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 2CB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Calithera Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.9%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 2CB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2CB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2CB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2CB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2CB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Susan Molineaux (65yo)

9.9yrs

Tenure

US$2,033,057

Compensation

Dr. Susan M. Molineaux, Ph.D., Co-founded Calithera Biosciences, Inc. in June 2010 and has been its Chief Executive Officer and President since June 2010. She focuses on Biopharmaceuticals. Dr. Molineaux a ...


CEO Compensation Analysis

Compensation vs Market: Susan's total compensation ($USD2.03M) is above average for companies of similar size in the German market ($USD811.49K).

Compensation vs Earnings: Susan's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Susan Molineaux
Co-Founder9.9yrsUS$2.03m0.85% $2.8m
Curtis Hecht
Chief Business Officer1.1yrsUS$883.44k0.044% $141.5k
Keith Orford
Chief Medical Officer3.8yrsUS$1.14m0.016% $51.6k
Stephanie Wong
Senior VP of Finance & Secretary0yrsno data0.079% $255.4k
Jennifer McNealey
Vice President of Investor Relations & Strategy3.2yrsno datano data
Sumita Ray
Senior VP2.3yrsUS$1.26mno data
Hagit Glickman
Head of People & Culture0yrsno datano data
Eric Sjogren
Senior Vice President of Drug Discovery9.7yrsUS$959.51k0.13% $435.1k
Christopher Molineaux
Senior Vice President of Development6.8yrsUS$446.60k0.0046% $15.1k
Sam Whiting
Senior Vice President of Clinical Development1.1yrsno datano data

3.5yrs

Average Tenure

48yo

Average Age

Experienced Management: 2CB's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Susan Molineaux
Co-Founder9.9yrsUS$2.03m0.85% $2.8m
Jean George
Independent Director7.4yrsUS$98.30kno data
Henry Wolff
Independent Director5.2yrsUS$97.30kno data
Deepika Pakianathan
Lead Independent Director3.1yrsUS$120.30kno data
Jonathan Drachman
Independent Director6.2yrsUS$87.30kno data
Sunil Agarwal
Independent Director4.4yrsUS$93.80kno data
Suzy Jones
Independent Director3.5yrsUS$89.80k0.013% $43.4k
Blake Wise
Director2.4yrsUS$86.05kno data

4.8yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 2CB's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.1%.


Top Shareholders

Company Information

Calithera Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Calithera Biosciences, Inc.
  • Ticker: 2CB
  • Exchange: DB
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$357.068m
  • Listing Market Cap: US$324.682m
  • Shares outstanding: 53.78m
  • Website: https://www.calithera.com

Number of Employees


Location

  • Calithera Biosciences, Inc.
  • 343 Oyster Point Boulevard
  • Suite 200
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CALANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2014
2CBDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014
2CBBRSE (Berne Stock Exchange)YesCommon StockCHCHFOct 2014

Biography

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/28 22:38
End of Day Share Price2020/02/28 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.